NASDAQ: BCYC | Healthcare / Biotechnology / United Kingdom |
26.25 | +0.3400 | +1.31% | Vol 276.65K | 1Y Perf -10.44% |
Aug 12th, 2022 16:00 DELAYED |
BID | 21.00 | ASK | 26.62 | ||
Open | 26.41 | Previous Close | 25.91 | ||
Pre-Market | - | After-Market | - | ||
- - | - -% |
Target Price | 63.50 | Analyst Rating | Strong Buy 1.42 | |
Potential % | 141.91 | Finscreener Ranking | — - | |
Insiders Trans % 3/6/12 mo. | -/-/-100 | Value Ranking | ★★★★ 56.78 | |
Insiders Value % 3/6/12 mo. | -/-/-100 | Growth Ranking | — - | |
Insiders Shares Cnt. % 3/6/12 mo. | -/-/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 28.34 | Earnings Rating | Strong Sell | |
Market Cap | 779.00M | Earnings Date | 4th Aug 2022 | |
Alpha | 0.02 | Standard Deviation | 0.20 | |
Beta | 0.53 |
Today's Price Range 25.300.00 | 52W Range 12.0862.08 |
Summary:
Buy
Technical Indicators: | Neutral |
Moving Averages: | Strong Buy |
Performance | |||
---|---|---|---|
1 Week | 0.19% | ||
1 Month | 22.78% | ||
3 Months | 51.30% | ||
6 Months | -46.15% | ||
1 Year | -10.44% | ||
3 Years | 243.14% | ||
5 Years | - | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -35.52 | |||
ROE last 12 Months | -38.42 | |||
ROA (5Y Avg) | -8.69 | |||
ROA last 12 Months | -25.94 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -31.95 | |||
Return on invested Capital Q | -7.31 | |||
Return on invested Capital Y | -5.82 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.40 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-8.60 | ||||
2.47 | ||||
47.05 | ||||
- | ||||
-14.10 | ||||
-1.36 | ||||
2.47 | ||||
10.49 | ||||
441.68M | ||||
Forward PE | -6.48 | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
9.70 | ||||
9.90 | ||||
0.12 | ||||
0.15 | ||||
-25.70 | ||||
Leverage Ratio | 1.40 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
-525.00 | ||||
-514.10 | ||||
-464.40 | ||||
- |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
16.34M | ||||
0.55 | ||||
- | ||||
- |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q02 2022 | -0.82 | -0.90 | -9.76 |
Q01 2022 | -0.70 | -0.93 | -32.86 |
Q04 2021 | -0.60 | -0.63 | -5.00 |
Q03 2021 | -0.67 | -0.59 | 11.94 |
Q02 2021 | -0.72 | -0.74 | -2.78 |
Q01 2021 | -0.66 | -0.73 | -10.61 |
Q04 2020 | -0.50 | -0.83 | -66.00 |
Q03 2020 | -0.66 | -0.52 | 21.21 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
6/2022 QR | -0.82 | -6.49 | Negative |
9/2022 QR | -0.87 | -7.41 | Negative |
12/2022 FY | -3.51 | -15.08 | Negative |
12/2023 FY | -4.04 | -4.94 | Negative |
Next Report Date | - |
Estimated EPS Next Report | -0.82 |
Estimates Count | 8 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 276.65K |
Shares Outstanding | 29.68K |
Shares Float | 29.02M |
Trades Count | 3.48K |
Dollar Volume | 7.20M |
Avg. Volume | 275.43K |
Avg. Weekly Volume | 243.34K |
Avg. Monthly Volume | 223.30K |
Avg. Quarterly Volume | 359.66K |
Bicycle Therapeutics plc (NASDAQ: BCYC) stock closed at 26.25 per share at the end of the most recent trading day (a 1.31% change compared to the prior day closing price) with a volume of 276.65K shares and market capitalization of 779.00M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 81 people. Bicycle Therapeutics plc CEO is Kevin Lee.
The one-year performance of Bicycle Therapeutics plc stock is -10.44%, while year-to-date (YTD) performance is -56.88%. BCYC stock has a five-year performance of %. Its 52-week range is between 12.08 and 62.075, which gives BCYC stock a 52-week price range ratio of 28.34%
Bicycle Therapeutics plc currently has a PE ratio of -8.60, a price-to-book (PB) ratio of 2.47, a price-to-sale (PS) ratio of 47.05, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -25.94%, a ROC of -31.95% and a ROE of -38.42%. The company’s profit margin is -%, its EBITDA margin is -514.10%, and its revenue ttm is $16.34 Million , which makes it $0.55 revenue per share.
Of the last four earnings reports from Bicycle Therapeutics plc, there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.82 for the next earnings report. Bicycle Therapeutics plc’s next earnings report date is -.
The consensus rating of Wall Street analysts for Bicycle Therapeutics plc is Strong Buy (1.42), with a target price of $63.5, which is +141.91% compared to the current price. The earnings rating for Bicycle Therapeutics plc stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Bicycle Therapeutics plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Bicycle Therapeutics plc has a Buy technical analysis rating based on Technical Indicators (ADX : 10.87, ATR14 : 1.96, CCI20 : 80.56, Chaikin Money Flow : 0.17, MACD : 2.05, Money Flow Index : 57.46, ROC : 7.80, RSI : 60.60, STOCH (14,3) : 64.19, STOCH RSI : 0.07, UO : 55.35, Williams %R : -35.81), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Bicycle Therapeutics plc in the last 12-months were: Alistair Milnes (Option Excercise at a value of $103 719), Dominic Smethurst (Option Excercise at a value of $111 300), Kevin Lee (Option Excercise at a value of $491 652), Kevin Lee (Sold 55 118 shares of value $2 250 189 ), Nicholas Keen (Option Excercise at a value of $216 678), Nicholas Keen (Sold 18 321 shares of value $774 682 ), Pierre Legault (Option Excercise at a value of $1 269 686), Pierre Legault (Sold 150 000 shares of value $8 653 889 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need.
CEO: Kevin Lee
Telephone: +44 1223261503
Address: B900, Babraham Research Campus, Cambridge CB22 3AT, , GB
Number of employees: 81
Fri, 05 Aug 2022 04:53 GMT Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Bicycle Therapeutics (BCYC) and OrthoPediatrics (KIDS)
- TipRanks. All rights reserved.Mon, 06 Jun 2022 04:25 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Bicycle Therapeutics (BCYC), Turning Point Therapeutics (TPTX) and Globus Medical (GMED)
- TipRanks. All rights reserved.Thu, 03 Mar 2022 10:18 GMT Bicycle Therapeutics (BCYC) Gets a Buy Rating from Leerink Partners
- TipRanks. All rights reserved.Wed, 02 Mar 2022 11:28 GMT Bicycle Therapeutics (BCYC) Receives a Buy from H.C. Wainwright
- TipRanks. All rights reserved.Thu, 06 Jan 2022 05:16 GMT Bicycle Therapeutics (BCYC) Received its Third Buy in a Row
- TipRanks. All rights reserved.Wed, 05 Jan 2022 14:35 GMT Bicycle Therapeutics (BCYC) Gets a Buy Rating from Needham
- TipRanks. All rights reserved.Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE EDGX Top real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2022. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.